Skip to main content

Advertisement

Table 4 Association between infecting pfcrt, pfmdr1, pfdhfr and pfdhps genotypes and treatment failure with amodiaquine plus sulphadoxine-pyrimethamine

From: The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea

CQ-relevant markers SP-relevant markers     
pfcrt pfmdr1 * pfdhfr pfdhps     
K76T N326D I356L A220S N86Y S108N C59R A437G K540E P (%) OR 95% CI p2)
          1.2 §   
      X     0.6 §   
      X X    1.7 §   
X          0.6 §   
X      X X    0.6 §   
X X X    X X    0.6 §   
X X X X       0.6 §   
X X X X   X     0.6 §   
X X X X   X X    7.0 0.28 0.03–2.24 0.16
     X      0.6 §   
     X X     1.2 §   
     X X X    3.5 1.67 0.29–9.48 0.57
X     X X X    0.6 §   
X X X   X      0.6 §   
X X X   X X     1.2 §   
X X X   X X X    11.7 1.10 0.38–3.25 0.86
X X X   X X X X   3.5 3.46 0.67–17.86 0.15
X X X X X      3.5 7.17 1.26–40.71 0.02
X X X X X     X 1.2 §   
X X X X X X     6.4 §   
X X X X X X X    42.7 1.00 0.48–2.03 0.98
X X X X X X X X   9.3 3.84 1.34–11.03 <0.01
X X X X X X X   X 0.6 §   
  1. * due to very low mutation rates, genotypes with mutated gene loci Y184F and N1042D in pfmdr1 were grouped together with the wild-type pfmdr1 genotypes; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; P, prevalence; OR, odds ratio; X, mutated allele; § the genotype was not detected in samples from treatment failure cases